Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 1/20 | 0.56 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.56 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.56 |
| ▸ | HTR2A | P28223 | 1/20 | 0.56 |
| ▸ | HTR2C | P28335 | 1/20 | 0.56 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.56 |
| ▸ | HRH1 | P35367 | 1/20 | 0.56 |
| ▸ | DRD3 | P35462 | 1/20 | 0.56 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.56 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.56 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | CA2 | P00918 | 7/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 3/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.48 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3014658 | 0.86 | CA2 (0.68) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| SCHEMBL165103 | 0.84 | CA2 (0.44) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| SCHEMBL30320036 | 0.81 | GABRR1 (0.43) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| SCHEMBL3020777 | 0.81 | CA2 (0.56) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| SCHEMBL9222116 | 0.81 | HDAC1 (0.52) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| SCHEMBL1300143 | 0.81 | FOLH1 (0.46) | HDAC1HDAC2HDAC8 | |
| Hydrochloric Acid SCHEMBL30807529 | 0.81 | CA2 (0.55) | CA2MAPK1SLC1A2SLC1A1GRIK1 | |
| SCHEMBL8249346 | 0.80 | CHRM1 (0.50) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| SCHEMBL9196088 | 0.80 | CHRM1 (0.50) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| SCHEMBL3019208 | 0.79 | CHRM1 (0.50) | CHRM1AKR1A1CHRM3HTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1635806-B1 | METHOD FOR TREATING ALCOHOLIC HEPATITIS | UNIV PITTSBURGH (US) | 2008-05-28 | — | — | EP | claimed |
| EP-1494659-B1 | PHARMACEUTICAL COMPOSITION COMPRISING AN ALPHA-KETOALKANOIC ACID ESTER OR -AMIDE AND LACTIC ACID OR A LACTIC ACID SALT | CRITICAL THERAPEUTICS INC (US) | 2005-10-12 | — | — | EP | claimed |
| WO-2020002138-A1 | C5 OR C6 ACID ESTER-BASED CATALYST AND USE THEREOF IN A HYDROPROCESSING AND/OR HYDROCRACKING PROCESS | IFP Energies Nouvelles (FR) | 2020-01-02 | — | — | WO | disclosed |
| EP-1437401-B1 | Oxidoreductase | IEP GMBH (DE) | 2010-12-15 | — | — | EP | disclosed |
| US-20100204161-A1 | Substances and Pharmaceutical Compositions for the Inhibition of Glyoxalases and Their Use Against Bacteria | BIOMAC PRIVATINSTITUT FUR MEDIZINISHE UND ZAHMEDIZ FORSCHUNG, ENTWICKLUNG UND DIAGNOSTIK GMBH (DE) | 2010-08-12 | — | — | US | disclosed |
| US-20100040607-A1 | Combination Therapy with Inhibitors of HMGB and Caspase for the Treatment of Inflammatory Diseases | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-02-18 | — | — | US | disclosed |
| US-20100040608-A1 | Use of HMGB1 antagonists for the treatment of inflammatory skin conditions | THE FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH | 2010-02-18 | — | — | US | disclosed |
| US-20080300303-A1 | Substances and Pharmaceutical Compositions for the Inhibition of Glyoxalases and Their Use As Anti-Fungal Agents | BIOMAC PRIVATINSTITUT FUER MEDIZINISCHE UND ZAHNMEDIZINISCHE FORSCHUNG, ENTWICKLUNG UND DIAGNOSTIK GMBH (DE) | 2008-12-04 | — | — | US | disclosed |
| EP-1924327-A2 | SUBSTANCES AND PHARMACEUTICAL COMPOSITIONS FOR THE INHIBITION OF GLYOXALASES AND THEIR USE TO COMBAT CANCER | Biomac Privatinstitut für medizinische und Zahnmedizinische Forschung, Entwicklung und Diagnostik GmbH (DE) | 2008-05-28 | — | — | EP | disclosed |
| EP-1909834-A2 | USE OF HMGB1 ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY SKIN CONDITIONS | Critical Therapeutics, Inc. (US) | 2008-04-16 | — | — | EP | disclosed |
| EP-1907003-A2 | COMBINATION THERAPY WITH INHIBITORS OF HMGB AND CASPASE FOR THE TREATMENT OF INFLAMMATORY DISEASES | The Feinstein Institute for Medical Research (US) | 2008-04-09 | — | — | EP | disclosed |
| EP-1814576-A2 | COMBINATION THERAPIES OF HMGB AND COMPLEMENT INHIBITORS AGAINST INFLAMMATION | Critical Therapeutics, Inc. (US) | 2007-08-08 | — | — | EP | disclosed |
| WO-2007011606-A2 | USE OF HMGBl ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY SKIN CONDITIONS | CRITICAL THERAPEUTICS, INC. (US) | 2007-01-25 | — | — | WO | disclosed |
| WO-2006124477-A2 | COMBINATION THERAPY WITH INHIBITORS OF HMGB AND CASPASE FOR THE TREATMENT OF INFLAMMATORY DISEASES | THE FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH (US) | 2006-11-23 | — | — | WO | disclosed |
| WO-2006108682-A2 | SUBSTANCES AND PHARMACEUTICAL COMPOSITIONS FOR THE INHIBITION OF GLYOXALASES AND THEIR USE AS ANTI-FUNGAL AGENTS | BIOMAC PRIVATINSTITUT FÜR MEDIZINISCHE UND ZAHNMEDIZINISCHE FORSCHUNG, ENTWICKLUNG UND DIAGNOSTIK GMBH (DE) | 2006-10-19 | — | — | WO | disclosed |
| WO-2006108680-A2 | SUBSTANCES AND PHARMACEUTICAL COMPOSITIONS FOR THE INHIBITION OF GLYOXALASES AND THEIR USE AGAINST PROTOZOA AND HELMINTHES | BIOMAC PRIVATINSTITUT FÜR MEDIZINISCHE UND ZAHNMEDIZINISCHE FORSCHUNG, ENTWICKLUNG UND DIAGNOSTIK GMBH (DE) | 2006-10-19 | — | — | WO | disclosed |
| WO-2006108679-A2 | SUBSTANCES AND PHARMACEUTICAL COMPOSITIONS FOR THE INHIBITION OF GLYOXALASES AND THEIR USE TO COMBAT CANCER | BIOMAC PRIVATINSTITUT FÜR MEDIZINISCHE UND ZAHNMEDIZINISCHE FORSCHUNG, ENTWICKLUNG UND DIAGNOSTIK GMBH (DE) | 2006-10-19 | — | — | WO | disclosed |
| WO-2006108681-A2 | SUBSTANCES AND PHARMACEUTICAL COMPOSITIONS FOR THE INHIBITION OF GLYOXALASES AND THEIR USE AGAINST BACTERIA | BIOMAC PRIVATINSTITUT FÜR MEDIZINISCHE UND ZAHNMEDIZINISCHE FORSCHUNG, ENTWICKLUNG UND DIAGNOSTIK GMBH (DE) | 2006-10-19 | — | — | WO | disclosed |
| WO-2006012373-A2 | COMBINATION THERAPIES OF HMGB AND COMPLEMENT INHIBITORS AGAINST INFLAMMATION | CRITICAL THERAPEUTICS, INC. (US) | 2006-02-02 | — | — | WO | disclosed |
| EP-1437401-A1 | Oxidoreductase | Juelich Enzyme Products GmbH (DE) | 2004-07-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300303-A1 | Substances and Pharmaceutical Compositions for the Inhibition of Glyoxalases and Their Use As Anti-Fungal Agents | GLO1, G6PD, GRHPR | CHRM1 298/4885AKR1A1 30/4885CHRM3 1057/4885 |
| US-20100040607-A1 | Combination Therapy with Inhibitors of HMGB and Caspase for the Treatment of Inflammatory Diseases | HMGB2, HMGB3, HMGB1 | CHRM1 4834/4885AKR1A1 2554/4885CHRM3 4580/4885 |
| US-20100204161-A1 | Substances and Pharmaceutical Compositions for the Inhibition of Glyoxalases and Their Use Against Bacteria | GLO1, G6PD, GRHPR | CHRM1 274/4885AKR1A1 26/4885CHRM3 1005/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.